KLRA financial statements
The full income statement, balance sheet, and cash-flow statement for Kailera Therapeutics Inc. (KLRA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 121M | 84.7M | ||
| Research & development | 101M | 70.9M | |
| Selling, general & administrative | 20.3M | 13.8M | |
| General & administrative | 20.3M | 13.8M | |
| Operating income | -121M | -84.7M | |
| Other non-operating income | 72.0K | 5.79M | |
| Net income | -111M | -78.9M | |
| -$1.09 | -$3650.00 | ||
| EPS (basic) | -$1.09 | -$3650.00 | |
| Weighted-avg shares (basic) | 102M | — | |
| Weighted-avg shares (diluted) | 102M | — | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 929M | 530M | ||
| Cash & equivalents | 130M | 112M | |
| Short-term investments | 786M | 407M | |
| Cash & short-term investments | 1.17B | 582M | |
| Prepaid expenses | 12.4M | 11.1M | |
| Other current assets | 395K | 360K | |
| 1.21B | 625M | ||
| Property, plant & equipment | 1.75M | 1.85M | |
| Operating lease right-of-use | 9.90M | 10.2M | |
| Long-term investments | 255M | 62.7M | |
| Other non-current assets | 90.0K | 5.59M | |
| 83.7M | 54.8M | ||
| Accounts payable | 19.2M | 7.09M | |
| Accrued liabilities | 63.4M | 46.7M | |
| Current lease liability | 1.05M | 1.03M | |
| 93.0M | 64.5M | ||
| Non-current lease liability | 9.17M | 9.44M | |
| Operating lease liability (total) | 10.2M | 10.5M | |
| Other non-current liabilities | 135K | 201K | |
| 1.12B | -432M | ||
| Preferred stock | 0.00 | — | |
| Common stock | 0.00 | 0.00 | |
| Additional paid-in capital | 1.68B | 16.0M | |
| Retained earnings | -559M | -448M | |
| Accumulated other comprehensive income | -1.79M | -532K | |
| Total liabilities & equity | 1.21B | 625M | |
| Common shares issued | 130M | — | |
| Common shares outstanding | 130M | — | |
| Shares outstanding (cover) | 130M | 130M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -77.5M | -68.3M | ||
| Depreciation & amortization | 101K | 101K | |
| Share-based compensation | 8.34M | 3.94M | |
| Change in payables | 12.3M | -495K | |
| -571M | 22.8M | ||
| Acquisitions | 0.00 | 0.00 | |
| 667M | -2.98M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 668M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 2.86B | — | |
| P/B | 2.6× | — | |
| Source filing | 10-Q | 10-Q |
About this data
Source: KLRA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all KLRA filings on SEC EDGAR → Not investment advice.